UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/923,385	08/08/2001	Leslie Dennis Michelson	16602.003	2406

28381 7590 12/04/2002

ARNOLD & PORTER
IP DOCKETING DEPARTMENT; RM 1126(b)
555 12TH STREET, N.W.
WASHINGTON, DC 20004-1206

EXAMINER
KALINOWSKI, ALEXANDER G

ART UNIT	PAPER NUMBER
3626	

DATE MAILED: 12/04/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.	Applicant(s)
09/923,385	Michelson et al.
Examiner	**Art Unit**
Alexander Kalinowski	3626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) ☒ Responsive to communication(s) filed on *Aug 8, 2001* .

2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.

3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

4) ☒ Claim(s) *1-15 and 121-128* is/are pending in the application.

4a) Of the above, claim(s) _____ is/are withdrawn from consideration.

5) ☐ Claim(s) _____ is/are allowed.

6) ☒ Claim(s) *1-15 and 121-128* is/are rejected.

7) ☐ Claim(s) _____ is/are objected to.

8) ☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

9) ☐ The specification is objected to by the Examiner.

10) ☐ The drawing(s) filed on _____ is/are a) ☐ accepted or b) ☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) ☒ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) ☐ All b) ☐ Some* c) ☐ None of:

1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

a) ☐ The translation of the foreign language provisional application has been received.

15) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s). 5
4) ☐ Interview Summary (PTO-413) Paper No(s). _____
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other:

DETAILED ACTION

1. Claims 1-15 and 121-128 are presented for examination. Applicant filed a petition to make special on 8/8/2001. The petition to make special was granted on 8/12/2002.

Oath/Declaration

2. The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because:

Applicant claimed priority to a previously filed PCT application that was filed prior to the instant application but the declaration does not contain the required identification of the prior filed PCT application (see MPEP 602).

Claim Rejections - 35 USC § 112

3.The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claim 4 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claim recites the limitation "the questionnaire" in line 6. There is insufficient antecedent basis for this limitation in the claim. For purposes of applying prior art, the Examiner

will assume that claim 4 is dependent upon claim 2 and sufficient antecedent basis exists for the limitation "the questionnaire".

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

6. Claims 1-5, 7-12, and 121-128 are rejected under 35 U.S.C. 103(a) as being unpatentable over information published at www.centerwatch.com (hereinafter CenterWatch) in view of Colon et al., Pat No. 5,991,731 (hereinafter Colon).

As to claim 1, CenterWatch discloses a method for recruiting a person to participate as a subject in a clinical study, comprising the steps of:

(a) presenting one or more web pages that allow the person or a caregiver associated with the person to register with a web site by submitting registration information to the web site, wherein the registration information includes at least a geographic location of the person, at least one disease condition of interest to the person, contact information, and permission information indicating whether the person or caregiver wishes to receive notice of one or more clinical studies

(i.e. Patient Notification Service web pages, email address, therapeutic areas, geographic regions, address, "unsubscribe")(Patient Notification Service, pages 1-3);

(b) automatically registering the person or caregiver with the web site upon receipt of the registration and permission information (i.e. if you're a patient or patient advocate seeking information about clinical trials ... then sign up here)(CenterWatch Clinical Trials Listing Service Home Page, page 1);

© after step (b), automatically determining, in accordance with the permission information and the registration information, whether to provide the person or caregiver with notice of a given clinical study associated with a disease condition of interest to the person (i.e. would like to be notified by e-mail of future trial postings to this site in a particular therapeutic area ...)(CenterWatch Clinical Trials Listing Service Home Page, page 1); and

(d) providing the person or caregiver notice of the given clinical study only if a determination is made in step © to provide such notice (i.e. would like to be notified by e-mail of future trial postings to this site in a particular therapeutic area ...)(CenterWatch Clinical Trials Listing Service Home Page, page 1).

CenterWatch does not explicitly disclose

allowing the person or caregiver to register with a database.

However, Colon discloses allowing the person or caregiver to register with a database (i.e. computing center 10 has a database host computer 11 ... patient data is entered relating to identification, demographics, and medical conditions ... after data is sent to the study management

center 10, server computer executes a test to see if patient meets eligibility parameters for the study ...)(col. 1, lines 58-63 and col. 6, lines 22-52). It would have been obvious to one of ordinary skill int eh art at the time of Applicant's invention to include allowing the person or caregiver to register with a database as disclosed by Colon within the CenterWatch method for the motivation of automatically assigning thousands of participants in a clinical study with respect to care strategies to be administered to study participants (col. 1, lines 42-51).

As to claim 2, CenterWatch does not explicitly disclose the method of claim l, further comprising the steps of:

(e) automatically presenting a questionnaire associated with the given clinical study to the person or caregiver after step (d); and

(f) storing answers submitted by the person or caregiver in the database.

However, Colon discloses (e) automatically presenting a questionnaire associated with the given clinical study to the person or caregiver after step (d); and (f) storing answers submitted by the person or caregiver in the database (i.e. the study will also include followup visits and the operation of the system for these consultations with a physician at participating sites ... followup data, endpoint data and significant events data is entered and after verification is transmitted through the Internet server 13 to the database host computer 11 for input to tables 51, 52, 53.)(col. 7, lines 8-37). It would have been obvious to one of ordinary skill in the art at the time of Applicant's invention to include (e) automatically presenting a questionnaire associated with

the given clinical study to the person or caregiver after step (d); and(f) storing answers submitted by the person or caregiver in the database as disclosed by Colon within the CenterWatch method for the motivation of automatically assigning thousands of participants in a clinical study with respect to care strategies to be administered to study participants (col. 1, lines 42-51).

As to claim 3, CenterWatch discloses the method of claim 2, further comprising the step of

(g) accessing the information stored along with other information in the database to determine whether the person qualifies to participate as a subject in a clinical study different from the given clinical study after step (f) (i.e. listing of clinical trials "CenterWatch Study Information")(pages 1-2).

As to claim 4, CenterWatch does not explicitly disclose the method of claim 1, wherein the questionnaire includes criteria specified by a sponsor of the clinical study for determining whether the person is an eligible subject for the given clinical study.

However, Colon discloses the questionnaire includes criteria specified by a sponsor of the clinical study for determining whether the person is an eligible subject for the given clinical study (i.e. the study will also include followup visits and the operation of the system for these consultations with a physician at participating sites ... followup data, endpoint data and significant events data is entered and after verification is transmitted through the Internet server 13 to the

database host computer 11 for input to tables 51, 52, 53.)(col. 7, lines 8-37). It would have been obvious to one of ordinary skill in the art at the time of Applicant's invention to include the questionnaire includes criteria specified by a sponsor of the clinical study for determining whether the person is an eligible subject for the given clinical study as disclosed by Colon within the CenterWatch method for the motivation of automatically assigning thousands of participants in a clinical study with respect to care strategies to be administered to study participants (col. 1, lines 42-51).

As to claim 5, CenterWatch discloses the method of claim 1, wherein steps (a) and (b) are performed during a registration visit by the person or caregiver to a web site associated with the one or more web pages (i.e. if you're a patient or patient advocate seeking information about clinical trials ... then sign up here)(CenterWatch Clinical Trials Listing Service Home Page, page 1).

CenterWatch does not explicitly disclose

where step (d) includes notifying the person or caregiver of the given clinical study during a current or subsequent visit of the person or caregiver to the web site.

However, Colon discloses step (d) includes notifying the person or caregiver of the given clinical study during a current or subsequent visit of the person or caregiver to the web site (col. 6, lines 39-50). It would have been obvious to one of ordinary skill int eh art at the time of Applicant's invention to include where step (d) includes notifying the person or caregiver of the

given clinical study during a current or subsequent visit of the person or caregiver to the web site as disclosed by Colon within the CenterWatch method for the motivation of automatically assigning thousands of participants in a clinical study with respect to care strategies to be administered to study participants while the patient is in the doctor's office(col. 1, lines 42-51).

As to claim 7, CenterWatch discloses the method of claim 1, wherein the notice provided in step (d) is sent by electronic mail from a web site associated with the one or more web pages to an e-mail address of the person or caregiver (i.e. would like to be notified by e-mail of future trial postings to this site in a particular therapeutic area ...)(CenterWatch Clinical Trials Listing Service Home Page, page 1).

As to claim 8, CenterWatch and Colon do not explicitly disclose the method of claim 1, wherein the notice provided in step (d) is sent by regular mail to the person or caregiver.

However, the Examiner takes official notice that it was well known in the electronic arts to send requested notice information via mail. The motivation for delivering notice by regular mail is for the convenience of the requestor. It would have been obvious to one of ordinary skill int eh art at the time of Applicant's invention to include the notice provided in step (d) is sent by regular mail to the person or caregiver within the CenterWatch and Colon combination for the motivation stated above.

As to claim 9, CenterWatch and Colon do not explicitly disclose the method of claim 1, wherein the notice provided in step (d) is communicated by telephone to the person or caregiver.

However, the Examiner takes official notice that it was well known in the electronic arts to send notice information by telephone to a requestor. The motivation for delivering notice by telephone is for the convenience of the requestor. It would have been obvious to one of ordinary skill int eh art at the time of Applicant's invention to include the notice provided in step (d) is communicated by telephone to the person or caregiver within the CenterWatch and Colon combination for the motivation stated above.

As to claim 10, CenterWatch discloses the method of claim 1, wherein a determination is made to provide the person or caregiver with the notice in step © in accordance with a geographic location of the given clinical study (i.e. Patient Notification Service web pages, email address, therapeutic areas, geographic regions, address, "unsubscribe")(Patient Notification Service, pages 1-3.

As to claim 11, CenterWatch discloses the method of claim 1, wherein in step © a determination is made not to provide the person or caregiver with notice of the given clinical study (i.e. would like to be notified by e-mail of future trial postings to this site in a particular therapeutic area ...)(CenterWatch Clinical Trials Listing Service Home Page, page 1).

As to claim 12, CenterWatch discloses the method of claim 1, wherein in step (a) the registration information includes a user id, a password, electronic mail address or telephone number, zip code, first name or preferred name, gender, date of birth, whether the person is interested in clinical study information, new medical therapies, or participating in clinical studies (i.e. Patient Notification Service web pages, email address, therapeutic areas, geographic regions, address, "unsubscribe")(Patient Notification Service, pages 1-3) .

As to Claim 121, CenterWatch discloses a method for recruiting a person to participate as a subject in a clinical study, comprising:

(a) presenting one or more web pages that allow the person or a caregiver associated with the person to register with a web site by submitting registration information to the web page (i.e. Patient Notification Service web pages, email address, therapeutic areas, geographic regions, address, "unsubscribe")(Patient Notification Service, pages 1-3);

(b) registering automatically the person or caregiver with the web site upon receipt of the registration information (i.e. if you're a patient or patient advocate seeking information about clinical trials ... then sign up here)(CenterWatch Clinical Trials Listing Service Home Page, page 1);

© determining automatically in accordance with the registration information whether to provide the person or caregiver with notice of a given clinical study associated with a therapeutic area, disease, or condition of interest to the person (i.e. would like to be notified by e-mail of future

trial postings to this site in a particular therapeutic area ...)(CenterWatch Clinical Trials Listing Service Home Page, page 1); and

(d) providing the person or caregiver with notice of the given clinical study if a determination is made to provide such notice (i.e. would like to be notified by e-mail of future trial postings to this site in a particular therapeutic area ...)(CenterWatch Clinical Trials Listing Service Home Page, page 1).

CenterWatch does not explicitly disclose

allowing the person or caregiver to register with a database.

However, Colon discloses allowing the person or caregiver to register with a database (i.e. computing center 10 has a database host computer 11 ... patient data is entered relating to identification, demographics, and medical conditions ... after data is sent to the study management center 10, server computer executes a test to see if patient meets eligibility parameters for the study ...)(col. 1, lines 58-63 and col. 6, lines 22-52). It would have been obvious to one of ordinary skill int eh art at the time of Applicant's invention to include allowing the person or caregiver to register with a database as disclosed by Colon within the CenterWatch method for the motivation of automatically assigning thousands of participants in a clinical study with respect to care strategies to be administered to study participants (col. 1, lines 42-51).

As to Claim 122, CenterWatch discloses the method as in claim 121, wherein said information comprises a geographic location of the person, a therapeutic area, disease, or

condition of interest to the person, contact information, and permission information indicating whether the person or caregiver wishes to receive notice of one or more clinical studies (i.e. Patient Notification Service web pages, email address, therapeutic areas, geographic regions, address, "unsubscribe")(Patient Notification Service, pages 1-3.

As to Claim 123, CenterWatch discloses a method for recruiting a person to participate as a subject in a clinical study, comprising:

(a) presenting one or more web pages that allow the person or a caregiver associated with the person to transfer information about the person over the Internet to a web site (i.e. Patient Notification Service web pages, email address, therapeutic areas, geographic regions, address, "unsubscribe")(Patient Notification Service, pages 1-3);

(b) determining automatically in accordance with said information whether to provide the person or caregiver with notice of a given clinical study associated with a therapeutic area, disease, or condition of interest to the person (i.e. would like to be notified by e-mail of future trial postings to this site in a particular therapeutic area ...)(CenterWatch Clinical Trials Listing Service Home Page, page 1); and

© providing the person or caregiver with notice of the given clinical study if a determination is made to provide such notice (i.e. would like to be notified by e-mail of future trial postings to this site in a particular therapeutic area ...)(CenterWatch Clinical Trials Listing Service Home Page, page 1).

CenterWatch does not explicitly disclose

allowing the person or caregiver to register with a database.

However, Colon discloses allowing the person or caregiver to register with a database (i.e. computing center 10 has a database host computer 11 ... patient data is entered relating to identification, demographics, and medical conditions ... after data is sent to the study management center 10, server computer executes a test to see if patient meets eligibility parameters for the study ...)(col. 1, lines 58-63 and col. 6, lines 22-52). It would have been obvious to one of ordinary skill int eh art at the time of Applicant's invention to include allowing the person or caregiver to register with a database as disclosed by Colon within the CenterWatch method for the motivation of automatically assigning thousands of participants in a clinical study with respect to care strategies to be administered to study participants (col. 1, lines 42-51).

As to Claim 124, CenterWatch discloses the method as in claim 123, wherein said information comprises a geographic location of the person, a therapeutic area, disease, or condition of interest to the person, contact information, and permission information indicating whether the person or caregiver wishes to receive notice of one or more clinical studies (i.e. Patient Notification Service web pages, email address, therapeutic areas, geographic regions, address, "unsubscribe")(Patient Notification Service, pages 1-3).

As to Claim 125, CenterWatch does not explicitly disclose the method as in claim 123 further comprising registering said information in a database.

However, Colon discloses allowing the person or caregiver to register said information with a database (i.e. computing center 10 has a database host computer 11 ... patient data is entered relating to identification, demographics, and medical conditions ... after data is sent to the study management center 10, server computer executes a test to see if patient meets eligibility parameters for the study ...)(col. 1, lines 58-63 and col. 6, lines 22-52). It would have been obvious to one of ordinary skill int eh art at the time of Applicant's invention to include registering said information with a database as disclosed by Colon within the CenterWatch method for the motivation of automatically assigning thousands of participants in a clinical study with respect to care strategies to be administered to study participants (col. 1, lines 42-51).

As to Claim 126, CenterWatch discloses a method for recruiting a person to participate as a subject in a clinical study, comprising the step of presenting one or more web pages that allow the person or a caregiver associated with the person to transfer information about the person over the Internet to a web site (i.e. Patient Notification Service web pages, email address, therapeutic areas, geographic regions, address, "unsubscribe")(Patient Notification Service, pages 1-3).

CenterWatch does not explicitly disclose

transferring the information over the Internet to a database.

However, Colon discloses allowing the person or caregiver to register with a database (i.e. computing center 10 has a database host computer 11 ... patient data is entered relating to identification, demographics, and medical conditions ... after data is sent to the study management center 10, server computer executes a test to see if patient meets eligibility parameters for the study ...)(col. 1, lines 58-63 and col. 6, lines 22-52). It would have been obvious to one of ordinary skill int eh art at the time of Applicant's invention to include transferring the information over the Internet to a database as disclosed by Colon within the CenterWatch method for the motivation of automatically assigning thousands of participants in a clinical study with respect to care strategies to be administered to study participants (col. 1, lines 42-51).

As to Claim 127, CenterWatch discloses the method as in claim 126, wherein said information comprises geographic location, zip code of residence, e-mail address, and contact information (i.e. Patient Notification Service web pages, email address, therapeutic areas, geographic regions, address, "unsubscribe")(Patient Notification Service, pages 1-3).

As to Claim 128, CenterWatch does not explicitly disclose the method as in claim 126, wherein said information comprises specific information about said person's medical condition, disease status, symptoms, duration of illness, medications taken, and prior treatment options.

However, Colon discloses said information comprises specific information about said person's medical condition, disease status, symptoms, duration of illness, medications taken, and

prior treatment options (i.e. blood pressure data ... particular medical condition)(col. 4, lines 49-53). It would have been obvious to one of ordinary skill int eh art at the time of Applicant's invention to include said information comprises specific information about said person's medical condition, disease status, symptoms, duration of illness, medications taken, and prior treatment options as disclosed by Colon within the CenterWatch method for the motivation of automatically assigning thousands of participants in a clinical study with respect to care strategies to be administered to study participants (col. 1, lines 42-51).

7. Claim 6 is rejected under 35 U.S.C. 103(a) as being unpatentable over CenterWatch and Colon as applied to claim 5 above, and further in view of "Pharmaceutical industry Embraces Clinmark Dotcom" (hereinafter ClinMark).

As to claim 6, CenterWatch and Colon do not explicitly disclose the method of claim 5, wherein step (d) further includes providing a listing of information associated with the given clinical study in a personal library associated with the person or caregiver on the web site.

However, ClinMark discloses step (d) further includes providing a listing of information associated with the given clinical study in a personal library associated with the person or caregiver on the web site (i.e. electronic bulletin boards)(page 2). It would have been obvious to one of ordinary skill int eh art at the time of Applicant's invention to include step (d) further includes providing a listing of information associated with the given clinical study in a personal

library associated with the person or caregiver on the web site as disclosed by ClinMark within the CenterWatch and Colon method for the motivation of providing a forum for individuals with a common purpose to learn about trends and exchange information (page 2)

8. Claims 13 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over CenterWatch and Colon as applied to claim 1 above, and further in view of ClinMark.

As to claim 13, CenterWatch and Colon do not explicitly disclose the method of claim 1, wherein a determination is made to provide the person or caregiver with the notice in step © in accordance with a geographic location of an investigator associated with the study.

However, ClinMark discloses a determination is made to provide the person or caregiver with the notice in step © in accordance with a geographic location of an investigator associated with the study (i.e. ... searched for oncologists in the United States ...)(page 2). It would have been obvious to one of ordinary skill in the art at the time of Applicant's invention to include

As to claim 14, CenterWatch and Colon do not explicitly disclose the method of claim 2, wherein the answers submitted by the person or caregiver are provided by telephone, regular mail, facsimile, and other off-line sources.

However, ClinMark discloses the answers submitted by the person or caregiver are provided by telephone, regular mail, facsimile, and other off-line sources (i.e. Registration is

available at ... 888-CLINMAR)(page 2). It would have been obvious to one of ordinary skill in the art at the time of Applicant's invention to include the answers submitted by the person or caregiver are provided by telephone, regular mail, facsimile, and other off-line sources as disclosed by ClinMark within the CenterWatch and Colon method for the motivation of providing information in a convenient manner for the requestor.

9. Claim 15 is rejected under 35 U.S.C. 103(a) as being unpatentable over CenterWatch and Colon as applied to claim 1 above, and further in view of Larkin, Marilynn, "Where to find clinical trials on the Web"(hereinafter Larkin).

As to claim 15, CenterWatch and Colon do not explicitly disclose the method of claim 1, wherein the step of automatically determining further includes reference to genetic sequence information associated with a person registered in the database.

However, Larkin discloses the step of automatically determining further includes reference to genetic sequence information associated with a person registered in the database (i.e. ... uses the web to recruit for its international gene discovery project)(page 2). It would have been obvious to one of ordinary skill in the art at the time of Applicant's invention to include reference to genetic sequence information associated with a person registered in the database as disclosed

by Larkin within the CenterWatch and Colon combination for the motivation of learning about trials in specific diseases (page 2).

Conclusion

10. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

a. Pat. No. 6,081,786 discloses a system for guiding the selection of a therapeutic treatment regimen for a known disease.

b. Pat. No. 5,898,586 discloses a method for administering clinical trial material.

c. H958 discloses a physician data query system to obtain recent cancer treatment information.

d. "If you'd like to join a clinical trial discloses web sites that post clinical trials information.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alexander Kalinowski, whose telephone number is (703) 305-2398. The examiner can normally be reached on Monday to Thursday from 9:00 AM to 6:30 PM. In addition, the examiner can be reached on alternate Fridays.

If any attempt to reached the examiner by telephone is unsuccessful, the examiner's supervisor, Joseph Thomas, can be reached on (703) 305-9588. The fax telephone number for this group is (703) 305-7687 (for official communications including After Final communications labeled "Box AF").

Hand delivered responses should be brought to Crystal Park 5, 2451 Crystal Drive, Arlington, VA, 7th Floor, receptionist.

Alexander Kalinowski

Patent Examiner

Art Unit 3626

December 2, 2002